Among patients with cN2 breast cancer, they found that nodal pCR after NAST was associated with subtype, clinical and radiologic response, and Ki-67 expression, suggesting that SLNB could be recommended for patients with HER2+ or TNBC with cN2 if there is a complete response. This evidence concerns the gene MKI67 and breast cancer.